Skip to main content
AmigoFish

Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard

From BioCentury This Week · · 34 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Argenx the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Biosciences will add a second multi-indication product upon which it can run the strategy that has made autoimmune drug Vyvgart efgartigimod alfa a blockbuster. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the deal (https://www.biocentury.com/article/660284) and put it in the context of a new cohort of large-cap companies increasingly active in biotech M&A. The analysts also assess (https://www.biocentury.com/article/660067) how recent releases from Anthropic, NVIDIA, Google, OpenAI and Amazon fit into biopharma R&D workflows — and with one another. Finally, they analyze the 1H26 clinical and regulatory catalyst scorecard (https://www.biocentury.com/article/660159), which therapies hit their milestones, which missed, and what’s next through year-end. This episode of the BioCentury This Week podcast has been brought to you by CBRE (https://www.cbre.com/).

View full story: https://www.biocentury.com/article/660296

#BiotechMA #ArtificialIntelligence #DrugDevelopment #ClinicalTrials #Biopharma

00:01 - Sponsor Message: CBRE 01:57 - BioCentury AI Connector 05:47 - Argenx Acquires Forte 08:06 - Rise of Biotech Buyers 13:12 - AI Giants' Tech Stack 24:20 - Anthropic Enters Drug Development 27:41 - 2026 Catalyst

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)

Back to BioCentury This Week · Report a problem